BridgeBio Pharma Inc [BBIO] stock prices are up 2.95% to $79.11 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 6.92% over the last week, with a monthly amount glided 6.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on January 06, 2026, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $96. Previously, Bernstein started tracking the stock with Outperform rating on December 11, 2025, and set its price target to $94. Truist started tracking the stock assigning a Buy rating and suggested a price target of $66 on July 21, 2025. Jefferies initiated its recommendation with a Buy and recommended $70 as its price target on July 14, 2025. Oppenheimer upgraded its rating to Outperform for this stock on July 09, 2025, but kept the price target unchanged to $60. In a note dated June 17, 2025, Wolfe Research initiated an Outperform rating and provided a target price of $49 on this stock.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $28.10 and $78.58 over the past year. Currently, Wall Street analysts expect the stock to reach $88.89 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $79.11 at the most recent close of the market. An investor can expect a potential return of 12.36% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 353.78M for trailing twelve months, representing a surge of 4318.01%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.72%, Pretax Profit Margin comes in at -2.27%, and Net Profit Margin reading is -2.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is 0.47 and Total Capital is -0.78. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 3.88. As well, the Quick Ratio is 3.76, while the Cash Ratio is 2.97. Considering the valuation of this stock, the price to sales ratio is 43.09.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Jan 09 ’26 when 40000.0 shares were sold. Chief Executive Officer, Kumar Neil completed a deal on Jan 08 ’26 to sell 40000.0 shares. Meanwhile, Director KUMAR HALDEA REVOCABLE TRUST U bought 0.12 million shares on Jan 08 ’26.
